Literature DB >> 22836862

Evidence for treatment and survival disparities by age in pancreatic adenocarcinoma: a population-based analysis.

Sunil Amin1, Aimee L Lucas, Harold Frucht.   

Abstract

OBJECTIVES: Studies demonstrate safety and survival benefits of surgical resection in older individuals with pancreatic adenocarcinoma. We investigated treatment disparities by age.
METHODS: The Surveillance, Epidemiology, and End Results database for survival and treatment of pancreatic adenocarcinoma between 1983 and 2007 stratified by age: younger than 50 years, between 50 and 70 years, or older than 70 years. Kaplan-Meier curves and Cox proportional hazards models were used for survival differences, and logistic regression models were used for treatment disparities and the decision to refuse surgery.
RESULTS: A total of 45,509 patients had microscopically confirmed pancreatic adenocarcinoma. Of these, 7374 (16%) received surgery and 9842 (22%) received radiation. Younger patients were more likely to receive both surgery and radiation. The prevalence of surgery decreased from 21% for those younger than 50 years to 19% for those between 50 and 70 years to 13% for those older than 70 years (P < 0.001). Radiation decreased from 28% to 25% to 17% (P < 0.001). Overall survival decreased with increasing age at diagnosis, 10.4 months (age <50 years) to 9.1 months (age 50-70 years) to 6.4 months (age >70 years) controlling for stage, sex, race, radiation, and surgery (P < 0.001). Increasing age negatively predicted the odds of receiving both surgery and radiation and increased the likelihood of refusing surgery.
CONCLUSIONS: Treatment disparities exist by age despite advances in radiation and surgical treatment. Increased treatment in the elderly will increase overall survival from pancreatic adenocarcinoma.

Entities:  

Mesh:

Year:  2013        PMID: 22836862      PMCID: PMC3958965          DOI: 10.1097/MPA.0b013e31825f3af4

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  23 in total

1.  Pancreatectomy risk calculator: an ACS-NSQIP resource.

Authors:  Purvi Parikh; Mira Shiloach; Mark E Cohen; Karl Y Bilimoria; Clifford Y Ko; Bruce L Hall; Henry A Pitt
Journal:  HPB (Oxford)       Date:  2010-09       Impact factor: 3.647

2.  Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality.

Authors:  M Trede; G Schwall; H D Saeger
Journal:  Ann Surg       Date:  1990-04       Impact factor: 12.969

Review 3.  Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).

Authors:  Mariacristina Di Marco; Roberto Di Cicilia; Marina Macchini; Elisabetta Nobili; Silvia Vecchiarelli; Giovanni Brandi; Guido Biasco
Journal:  Oncol Rep       Date:  2010-05       Impact factor: 3.906

4.  Outcome after pancreaticoduodenectomy for cancer in elderly patients.

Authors:  Radu Scurtu; Philippe Bachellier; Elie Oussoultzoglou; Edoardo Rosso; Rodrigo Maroni; Daniel Jaeck
Journal:  J Gastrointest Surg       Date:  2006-06       Impact factor: 3.452

5.  Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer.

Authors:  Samuel Cykert; Peggye Dilworth-Anderson; Michael H Monroe; Paul Walker; Franklin R McGuire; Giselle Corbie-Smith; Lloyd J Edwards; Audrina Jones Bunton
Journal:  JAMA       Date:  2010-06-16       Impact factor: 56.272

6.  Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival.

Authors:  Mara A Schonberg; Edward R Marcantonio; Donglin Li; Rebecca A Silliman; Long Ngo; Ellen P McCarthy
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

7.  Outcomes in octogenarians undergoing high-risk cancer operation: a national study.

Authors:  Emily Finlayson; Zhaohui Fan; John D Birkmeyer
Journal:  J Am Coll Surg       Date:  2007-10-01       Impact factor: 6.113

8.  The effect of age on short-term outcomes after pancreatic resection: a population-based study.

Authors:  Taylor S Riall; Deepthi M Reddy; William H Nealon; James S Goodwin
Journal:  Ann Surg       Date:  2008-09       Impact factor: 12.969

9.  Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older.

Authors:  David T Miyamoto; Harvey J Mamon; David P Ryan; Christopher G Willett; Marek Ancukiewicz; Wendy K Kobayashi; Lawrence Blaszkowsky; Carlos Fernandez-del Castillo; Theodore S Hong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-09-30       Impact factor: 7.038

10.  A report of forty-four instances of pancreaticoduodenal resection in patients more than seventy years of age.

Authors:  L Hannoun; M Christophe; J Ribeiro; B Nordlinger; M Elriwini; E Tiret; R Parc
Journal:  Surg Gynecol Obstet       Date:  1993-12
View more
  12 in total

Review 1.  Update on the Management of Pancreatic Cancer in Older Adults.

Authors:  Shin Yin Lee; Moussa Sissoko; Kevan L Hartshorn
Journal:  Curr Oncol Rep       Date:  2016-10       Impact factor: 5.075

2.  National disparities in minimally invasive surgery for pancreatic tumors.

Authors:  Emmanuel Gabriel; Pragatheeshwar Thirunavukarasu; Kristopher Attwood; Steven J Nurkin
Journal:  Surg Endosc       Date:  2016-07-13       Impact factor: 4.584

3.  Age-related Survival Outcomes for Pancreatic Cancer by Age.

Authors:  Ali Abbaszadeh Kasbi; Mohammed Ali Ashary; Mizba Baksh; Samuel Nussbaum; Kristopher Attwood; Emmanuel Gabriel
Journal:  Cancer Diagn Progn       Date:  2022-01-03

4.  Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study.

Authors:  Citadel J Cabasag; Melina Arnold; Mark Rutherford; Aude Bardot; Jacques Ferlay; Eileen Morgan; Alana Little; Prithwish De; Elijah Dixon; Ryan R Woods; Nathalie Saint-Jacques; Sue Evans; Gerda Engholm; Mark Elwood; Neil Merrett; David Ransom; Dianne L O'Connell; Freddie Bray; Isabelle Soerjomataram
Journal:  Br J Cancer       Date:  2022-03-02       Impact factor: 9.075

5.  Disparities in Access to Oncologic Care in Pancreatic Cancer: A Systematic Review.

Authors:  Annabelle L Fonseca; Hamza Khan; Krista R Mehari; Deepa Cherla; Martin J Heslin; Fabian M Johnston
Journal:  Ann Surg Oncol       Date:  2022-01-23       Impact factor: 5.344

6.  Insurance Status Is Related to Receipt of Therapy and Survival in Patients with Early-Stage Pancreatic Exocrine Carcinoma.

Authors:  Emily Boevers; Bradley D McDowell; Sarah L Mott; Anna M Button; Charles F Lynch
Journal:  J Cancer Epidemiol       Date:  2017-04-10

7.  A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma.

Authors:  Kian-Huat Lim; Emma Langley; Feng Gao; Jingqin Luo; Lin Li; Gary Meyer; Phillip Kim; Sharat Singh; Vladamir M Kushnir; Dayna S Early; Daniel K Mullady; Steven A Edmundowicz; Sachin Wani; Faris M Murad; Dengfeng Cao; Riad R Azar; Andrea Wang-Gillam
Journal:  Oncotarget       Date:  2017-04-11

8.  Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a regional Cancer Centre.

Authors:  Olusola O Faluyi; Joanna L Connor; Madhuchanda Chatterjee; Carl Ikin; Helen Wong; Daniel H Palmer
Journal:  Br J Cancer       Date:  2017-01-12       Impact factor: 7.640

9.  Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis.

Authors:  Hani Oweira; Ulf Petrausch; Daniel Helbling; Jan Schmidt; Meinrad Mannhart; Arianeb Mehrabi; Othmar Schöb; Anwar Giryes; Michael Decker; Omar Abdel-Rahman
Journal:  World J Gastroenterol       Date:  2017-03-14       Impact factor: 5.742

10.  Novel regulatory program for norepinephrine-induced epithelial-mesenchymal transition in gastric adenocarcinoma cell lines.

Authors:  Tao Shan; Xijuan Cui; Wei Li; Wanrun Lin; Yiming Li; Xi Chen; Tao Wu
Journal:  Cancer Sci       Date:  2014-06-18       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.